Matches in Nanopublications for { ?s ?p "[Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1248182.RACTa9T0UCxKxPRX5svwWVAv5lrQ5tYp4ewytSxGt288U130_assertion description "[Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248182.RACTa9T0UCxKxPRX5svwWVAv5lrQ5tYp4ewytSxGt288U130_provenance.
- NP1248183.RA9hMoY9QSZCXo4clh4tVtxF1YSpIJscBpedI-Cu3WTuA130_assertion description "[Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248183.RA9hMoY9QSZCXo4clh4tVtxF1YSpIJscBpedI-Cu3WTuA130_provenance.